Oncology Institute, Inc. TOI

Rank #2373 · Nasdaq · $0.6B market cap

⚠ Going-concern flag — the auditor (BDO USA, P.C.) raised substantial doubt about this company's ability to continue operating in the latest filing. Read the actual filing before drawing conclusions.

Score

21.7

P/E

-9.1

P/B

10.33

ROE

-113.4%

Op. Margin

-15.3%

Debt Ratio

297%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆

Poor

P/E -9.1x, P/B 10.33x. Ranks in the top 83% of the universe.

Profitability ★☆☆☆☆

Poor

ROE -113.4%. Ranks in the top 88% of the universe.

Safety ★☆☆☆☆

Weak

Debt ratio 297%. Ranks in the top 71% of the universe. Above 200% signals meaningful leverage risk.

Growth ★★★★☆

Excellent

Revenue growth of 21.3% year over year. Ranks in the top 17% of the universe.

Growth is the relative strength · Valuation is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FY	Revenue	Op. Income	Net Income	Equity	Op. Margin%	Debt%
2020	–	$-0.0B	$-0.0B	$0.0B	–	–
2021	$0.2B	$-0.0B	$-0.0B	$0.0B	-4.4	89
2022	$0.2B	$-0.0B	$-0.0B	$0.0B	-22.6	353
2023	$0.3B	$-0.1B	$0.0B	$0.1B	-32.5	133
2024	$0.3B	$-0.1B	$-0.1B	$0.1B	-23.8	124
2025	$0.4B	$-0.1B	$-0.1B	$0.1B	-15.3	297

← See the full screener